Returns Chart

Key Stats

Net Expense Ratio Total Assets Under Management Weighted Average Dividend Yield Turnover Ratio (Generic)
2.50% 742.84M 1.70% 68.46%
1 Year Fund Level Flows 1 Year Total Returns (Daily) Annualized Total Returns Since Inception (Daily) Max Drawdown (Since Inception)
-5.252M 20.84% Upgrade Upgrade

Basic Info

Investment Strategy
The investment objective of the Fund is to obtain long-term capital appreciation by investing primarily in U.S. companies and global companies with U.S. operations or exposure to U.S. markets or whose securities are traded on a U.S. exchange, which are engaged in the design, development, manufacturing, and distribution of products or services in the health care sectors.The Fund will invest in a diversified portfolio, which will mainly include securities in the medical technology, biotechnology, health care, and pharmaceutical sectors.
General
Security Type Mutual Fund
Equity Style Large Cap Core
Broad Asset Class Miscellaneous
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Health Care Equity
Global Macro Equity Industry Sector
US Macro --
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective --
Fund Owner Firm Name Renaissance Investments
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%

View Basic Info
Start Trial

Net Fund Flows Versus Peer Group

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: 3
-38.14M Peer Group Low
74.26M Peer Group High
1 Year
% Rank: 38
-5.252M
-338.43M Peer Group Low
246.96M Peer Group High
3 Months
% Rank: 3
-186.09M Peer Group Low
59.76M Peer Group High
3 Years
% Rank: 89
-812.56M Peer Group Low
555.36M Peer Group High
6 Months
% Rank: 18
-181.73M Peer Group Low
92.55M Peer Group High
5 Years
% Rank: 52
-531.99M Peer Group Low
1.261B Peer Group High
YTD
% Rank: --
-975839.0 Peer Group Low
-975839.0 Peer Group High
10 Years
% Rank: 77
-322.46M Peer Group Low
1.506B Peer Group High
Date Unavailable

Performance Versus Peer Group

 
20%
15%
10%
5%
0
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (NAV)
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
Peer Group Rtn. (NAV)
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
12.00%
% Rank in Peer Group (NAV)
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
View Performance Versus Peer Group
Start Trial

Annual Total Returns Versus Peers

Loading chart...
Name
2019
2020
2021
2022
2023
2024
2025
YTD
16.38%
9.15%
8.24%
-6.72%
-2.51%
11.04%
18.39%
3.15%
21.93%
5.56%
28.04%
-6.24%
12.05%
21.04%
29.06%
3.18%
14.48%
11.18%
18.51%
0.49%
-1.00%
4.42%
7.29%
3.59%
11.71%
7.28%
17.63%
0.90%
-0.41%
11.00%
7.76%
2.74%
--
--
18.12%
-0.60%
2.99%
1.08%
11.44%
2.14%
2.74%
6.66%
6.09%
-7.78%
-0.76%
6.91%
-0.95%
2.65%
As of January 14, 2026.

Fundamentals

General
Distribution Yield --
Dividend Yield TTM (1-12-26) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings 10
Stock
Weighted Average PE Ratio 33.24
Weighted Average Price to Sales Ratio 6.671
Weighted Average Price to Book Ratio 8.999
Weighted Median ROE 35.47%
Weighted Median ROA 7.59%
ROI (TTM) 11.55%
Return on Investment (TTM) 11.55%
Earning Yield 0.0364
LT Debt / Shareholders Equity 2.404
Number of Equity Holdings 10
As of November 30, 2025

Growth Metrics

EPS Growth (1Y) 8.75%
EPS Growth (3Y) -1.86%
EPS Growth (5Y) 5.23%
Sales Growth (1Y) 9.93%
Sales Growth (3Y) 5.99%
Sales Growth (5Y) 6.68%
Sales per Share Growth (1Y) 10.16%
Sales per Share Growth (3Y) 7.53%
Operating Cash Flow - Growth Rate (3Y) 0.79%
As of November 30, 2025

Asset Allocation

As of November 30, 2025.
Type % Net
Cash 0.14%
Stock 97.64%
Bond 2.22%
Convertible 0.00%
Preferred 0.00%
Other -0.00%
View Asset Allocation
Start Trial

Top 10 Holdings

Name % Weight Price % Change
Eli Lilly & Co. 9.66% 1077.19 -0.35%
Johnson & Johnson 9.13% 213.65 1.87%
UnitedHealth Group, Inc. 8.62% 333.93 -1.93%
Roche Holding AG 7.70% 426.00 -0.19%
Thermo Fisher Scientific, Inc. 7.41% 607.08 -1.36%
Medtronic Plc 7.07% 96.42 -0.55%
Novartis AG 6.51% 137.66 -0.50%
AbbVie, Inc. 5.61% 220.75 0.32%
Amgen, Inc. 5.42% 324.30 -0.38%
Sanofi 4.92% 95.53 -1.57%

Fees & Availability

Fees
Actual 12B-1 Fee --
Actual Management Fee --
Administration Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
General Availability
Available for Insurance Product No
Available for RRSP Yes
Purchase Details
Open to New Investors Yes
Minimum Initial Investment 500.00 None
Minimum Subsequent Investment 50.00 None

Basic Info

Investment Strategy
The investment objective of the Fund is to obtain long-term capital appreciation by investing primarily in U.S. companies and global companies with U.S. operations or exposure to U.S. markets or whose securities are traded on a U.S. exchange, which are engaged in the design, development, manufacturing, and distribution of products or services in the health care sectors.The Fund will invest in a diversified portfolio, which will mainly include securities in the medical technology, biotechnology, health care, and pharmaceutical sectors.
General
Security Type Mutual Fund
Equity Style Large Cap Core
Broad Asset Class Miscellaneous
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Health Care Equity
Global Macro Equity Industry Sector
US Macro --
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective --
Fund Owner Firm Name Renaissance Investments
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%

View Basic Info
Start Trial

Fundamentals

General
Distribution Yield --
Dividend Yield TTM (1-12-26) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings 10
Stock
Weighted Average PE Ratio 33.24
Weighted Average Price to Sales Ratio 6.671
Weighted Average Price to Book Ratio 8.999
Weighted Median ROE 35.47%
Weighted Median ROA 7.59%
ROI (TTM) 11.55%
Return on Investment (TTM) 11.55%
Earning Yield 0.0364
LT Debt / Shareholders Equity 2.404
Number of Equity Holdings 10
As of November 30, 2025

Growth Metrics

EPS Growth (1Y) 8.75%
EPS Growth (3Y) -1.86%
EPS Growth (5Y) 5.23%
Sales Growth (1Y) 9.93%
Sales Growth (3Y) 5.99%
Sales Growth (5Y) 6.68%
Sales per Share Growth (1Y) 10.16%
Sales per Share Growth (3Y) 7.53%
Operating Cash Flow - Growth Rate (3Y) 0.79%
As of November 30, 2025

Fund Details

Key Dates
Launch Date 11/2/1996
Share Classes
ATL1635 Fee-based Advice
ATL1735 Institutional
Attributes
Inverse Fund No
Leveraged Fund --
Currency Hedged Fund --
Socially Responsible Fund No

Top Portfolio Holders

Name % Weight
Portfolio A 5.00%
Portfolio B 3.50%
Portfolio C 2.25%
View Top Portfolio Holders
Start Trial

Excel Add-In Codes

Name: =YCI("M:ATL1161.TO", "name")
Broad Asset Class: =YCI("M:ATL1161.TO", "broad_asset_class")
Broad Category: =YCI("M:ATL1161.TO", "broad_category_group")
Prospectus Objective: =YCI("M:ATL1161.TO", "prospectus_objective")
To find the codes for any of our securities and financial metrics, see our Complete Excel Reference.
View Excel Add-In Codes
Start Trial